Baldwin Wealth Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Baldwin Wealth Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,000	Closed	-$26K	–	551
2020 Q2	$26K	Hold	1,000	–	–	﹤0.01%	361
2020 Q1	$15K	Hold	1,000	–	–	﹤0.01%	399
2019 Q4	$34K	Hold	1,000	–	–	﹤0.01%	362
2019 Q3	$7K	Hold	1,000	–	–	﹤0.01%	469
2019 Q2	$13K	Hold	1,000	–	–	﹤0.01%	433
2019 Q1	$12K	Hold	1,000	–	–	﹤0.01%	443
2018 Q4	$11K	Hold	1,000	–	–	﹤0.01%	433
2018 Q3	$22K	Hold	1,000	–	–	﹤0.01%	396
2018 Q2	$18K	Hold	1,000	–	–	﹤0.01%	411
2018 Q1	$21K	Hold	1,000	–	–	﹤0.01%	378
2017 Q4	$14K	Buy	+1,000	New	+$15.4K	﹤0.01%	402

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baldwin Wealth Partners's ITCI Position: Q3 2020 in Review

Baldwin Wealth Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2020, closing a stake of 1,000 shares — an estimated $26K sold.

Baldwin Wealth Partners first reported a position in ITCI in Q4 2017 and held it in 11 quarters. The position peaked at $34K in Q4 2019. 176 funds tracked by Wall St. Rank hold ITCI as of Q3 2020.

Baldwin Wealth Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2020 after selling out during the quarter.
Baldwin Wealth Partners sold 1,000 Intra-Cellular Therapies Inc. shares in Q3 2020, an estimated $26K.
Baldwin Wealth Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2017 and held it in 11 quarters.
Baldwin Wealth Partners's Intra-Cellular Therapies Inc. position peaked at $34K in Q4 2019.
176 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2020.

Based on Baldwin Wealth Partners's 13F filing for Q3 2020, filed 16 Oct 2020.